Rybrevant
Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.
European Commission Approves J&J's Subcutaneous Rybrevant for Certain NSCLC Patients
The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.
CHMP Recommends Approval of J&J's Subcutaneous Rybrevant for Certain NSCLC Patients in Europe
The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
European Commission Approves Rybrevant, Lazcluze in EGFR-Mutated NSCLC
Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.